Chronic Myeloid Leukemia
Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic PhaseFebruary 09, 2017
Bosutinib outperformed imatinib as first-line therapy for patients with Ph+ chronic myeloid leukemia in chronic phase, according to trial data.
Results of this study reveal the impact on quality of life and consequent adherence to therapy for patients with CML-CP receiving nilotinib as second-line therapy.
Researchers evaluated the molecular response in patients with CML-CP treated with pioglitazone in combination with imatinib, the results of which suggest that adding pioglitazone to a kinase inhibitor may have a synergistic effect.
Researchers examined the frequency of TKI-induced hemorrhagic colitis among patients with CML treated with dasatinib and evaluated the efficacy of screening with a fecal occult blood test followed by colonoscopy in this patient population.
A report of an evaluation of the benefit of ibrutinib in relapsed CLL following allogeneic HSCT based on an analysis of data from patients with relapsed CLL who received ibrutinib salvage therapy after allogeneic HSCT.
In patients with chronic myeloid leukemia in chronic phase, prolonged treatment with imatinib helps to achieve a deeper molecular response over 5 years.
Inhibition of the protein Ezh2 causes chronic myelogenous leukemia (CML) stem cells to die. Adding drugs that target this protein to imatinib (Gleevec) or other BCR-ABL blockers could result in a cure for this disease.
The population-based EUTOS registry demonstrated high overall and progression-free survival rates among patients with chronic myeloid leukemia.
Dasatinib and nilotinib are associated with similar response rates and survival outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).
For patients with chronic myeloid leukemia treated with lifelong targeted therapies, social support is crucial for maintaining psychological well-being.
Tyrosine Kinase Inhibitor Therapy Can Be Safely Stopped in Select Patients With CML in Chronic PhaseJuly 29, 2016
A high percentage of patients with CML treated with TKIs achieve deep molecular responses and can safely stop therapy. Initials results of the EURO-SKI trial define prognostic markers that indicate durability of deep molecular responses after stopping TKI therapy.
In the era of tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation, the life expectancy of patients with CML is approaching that of the general population.
A study examined the impact of post-transplant maintenance TKIs on patients with Ph+ acute lymphoblastic leukemia and chronic myeloid leukemia.
Ponatinib treatment was compared with imatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CP-CML).
With the January 2016 expiration of the patent on Gleevac, significant cost savings can be realized by insurance companies and patients. Just 15 years ago, Gleevac (imatinib) changed chronic myeloid leukemia (CML) from a fatal disease to a treatable illness.
During the summer, many patients with CML who are taking oral chemotherapy drugs have questions about taking their drugs while traveling. What advice can we give them regarding this?
Lymphocytosis is associated with higher response rates, significantly longer response durations, and improved overall survival.
Dasatinib, nilotinib, and ponatinib, used in the treatment of patients with chronic myeloid leukemia (CML) increase vascular occlusive events.
For patients with chronic phase chronic myeloid leukemia (CP-CML) and the T315I mutation, ponatinib treatment may offer longer overall survival.
Nearly 25 percent of patients with chronic myeloid leukemia (CML) undergoing treatment with tyrosine kinase inhibitors are vulnerable to a a "withdrawal syndrome," a recent study reported.
Research indicates that adjustment of imatinib doses based on therapeutic drug monitoring can result in higher rates of major molecular response in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.
New research indicates that patients with chronic-phase chronic myeloid leukemia with deep molecular responses to TKIs have increased effector natural killer and cytotoxic T cell immune responses to leukemia-associated antigens.
Bosutinib continues to demonstrate durable long-term efficacy and manageable toxicity in patients with chronic myeloid leukemia (CML).
Patients with chronic myeloid leukemia who received imatinib plus pioglitazone achieved a sustained complete molecular response for up to 4.7 years after the withdrawal of the antidiabetes medication.
Tyrosine kinase inhibitors (TKIs) seem safe in patients with chronic myeloid leukemia (CML) in chronic-phase and chronic kidney disease.
What data are available concerning inter- and intrapatient variability in the pharmacokinetics of TKIs in chronic myeloid leukemia?
The FDA asked the manufacturer of ponatinib (Iclusig) to suspend marketing and sales of the drug, hydrocodone bitartrate extended-release capsules (Zohydro ER) gained FDA approval, and other FDA actions.
Two gene alterations pair up to promote the growth of leukemia cells and their escape from anticancer drugs, according to new research.
Patients with chronic myeloid leukemia (CML) who are treated with tyrosine kinase inhibitors (TKIs) have significant side effects and QOL issues that need to be addressed.
For patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia, activating mutations in the gene encoding the colony stimulating factor 3 receptor are common.
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors
- The Integration of Cannabis in Oncologic Care
- Single Fraction of HDR Brachytherapy Found Effective in Localized Prostate Cancer
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- The Integration of Cannabis in Oncologic Care
- CTCs Promising as Biomarker to Identify Lung Cancer Recurrence
- Hypofractionated RT, Conventional RT Comparable in Intermediate-Risk Prostate Cancer
- Social Functioning Scores for Young Cancer Survivors Remain Lower Than Their Peers
- Mortality Rates Highest Among Youngest Oncology Patients, Particularly Minorities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|